Zim Laboratories Ltd
Zim Laboratories Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
FY27 growth expected at 10-15% without EU-GMP certification, driven by base business and new hires. FY28 growth expected at 30-40% top-line if EU-GMP certification is obtained, leading to mid-teens EBITDA margin (Page 12).
From Zim Laboratories Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- FY27 growth expected at 10-15% without EU-GMP certification, driven by base business and new hires.
- FY28 growth expected at 30-40% if EU-GMP certification is obtained, with major value unlock from EU market entry.
- Revenue projection for FY28 around INR 500 crores subject to EU-GMP certification.
- Sales from innovative product portfolio and regulated market (NIP and Oral Thin Film) expected to contribute significantly post EU-GMP.
- Growth driven by expansion into regulated markets, new product launches, and improved organizational capabilities.
- Lag of about two quarters expected between EU-GMP certification and start of substantial supply and revenue impact.
- Base business expected to continue steady growth irrespective of EU-GMP timeline.
- Capable leadership and infrastructure in place to support targeted growth rates.
Profitability & Margins
See what Zim Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- CapEx for FY27 is mostly completed.
- Remaining CapEx mainly involves normal upgradation expenses.
- Planned CapEx of around INR 15-20 crores to upgrade the enzyme plant and Nutra plant.
- No major new capital investments announced beyond these upgrades.
- Focus has shifted towards operational improvements and leveraging existing assets.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zim Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has mentioned having 8 to 10 Market Authorizations (MAs) awaiting activation once EU-GMP certification is obtained.
- Some products are already being produced at alternate facilities as a risk mitigation measure.
- Inventory buildup is selective, focused on APIs for key products with longer lead times; other inventory is managed on a just-in-time basis.
- Orders from Australia have started, with supplies expected to begin within 2-3 months pending TGA certification.
- The supply start is expected to trigger significant revenue growth, particularly with the EU-GMP approval unlocking approximately 60-70% of projected growth.
- Overall, the company anticipates better visibility on order inflows and supply scale-up by Q2 FY27, post EU-GMP certification.
Zim Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹105 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zim Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Zim Laboratories Ltd Q1 FY27 results?
FY27 growth expected at 10-15% without EU-GMP certification, driven by base business and new hires. FY28 growth expected at 30-40% top-line if EU-GMP certification is obtained, leading to mid-teens EBITDA margin (Page 12).
What is Zim Laboratories Ltd share price analysis?
Zim Laboratories Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 141.2 with a market cap of ₹614 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zim Laboratories Ltd planning capital expenditure?
CapEx for FY27 is mostly completed.
Keep Zim Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.